A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial

Details

Serval ID
serval:BIB_C8711903FB6C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial
Journal
Journal of the American College of Cardiology
Author(s)
Goy  J. J., Stauffer  J. C., Siegenthaler  M., Benoit  A., Seydoux  C.
ISSN
0735-1097 (Print)
Publication state
Published
Issued date
01/2005
Volume
45
Number
2
Pages
308-11
Notes
Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Jan 18
Abstract
OBJECTIVES: We conducted this trial to assess whether a sirolimus-eluting stent (SES) produces similar results to a paclitaxel-eluting stent (PES) when used in the real world of interventional cardiology. BACKGROUND: Several drug-eluting stents have been shown to exert a beneficial effect on restenosis when used in the treatment of coronary artery disease. Any potential superiority of one drug over the others, however, is still unknown. METHODS: To evaluate whether a PES or an SES is superior in daily practice, we randomized all patients suitable to receive a drug-eluting stent in our institution. Clinical follow-up was obtained after at least six months. RESULTS: A total of 202 patients were included in this trial. One hundred patients received a PES and 102 received an SES. Procedural success was 99% in both groups. Incidence of major adverse cardiac events at follow-up (mean 7 +/- 2 months) was 4% with the PES and 6% with the SES (p = 0.8). The need for target lesion revascularization was very low in both groups (1% with the PES and 3% with the SES). CONCLUSIONS: Our results confirm that the high success rate obtained with both stents in randomized trials can be replicated in routine clinical practice. In this small group of patients we were unable to show any advantage of one stent over the other.
Keywords
Aged Angioplasty, Transluminal, Percutaneous Coronary Coronary Arteriosclerosis/*therapy Female Follow-Up Studies Graft Occlusion, Vascular/*prevention & control Humans Immunosuppressive Agents/*administration & dosage Male Middle Aged Paclitaxel/*administration & dosage Prospective Studies Sirolimus/*administration & dosage *Stents Treatment Outcome
Pubmed
Web of science
Open Access
Yes
Create date
28/01/2008 11:11
Last modification date
20/08/2019 16:43
Usage data